trial
as of 2026-07-01A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
NCTId NCT03818256
at a glance
Phase 2 · Completed
Enrollment 71 (actual)
Sponsored by Corcept Therapeutics
Primary completion 2022-06-17
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
71 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2019-12-04
Primary completion
2022-06-17
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Corcept TherapeuticsLead Sponsor
Investigators
1
Kavita Juneja, MDStudy Director
Sites
27 total
Bentonville, United StatesLittle Rock, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesOakland, United StatesOceanside, United StatesRancho Cucamonga, United StatesMiami, United StatesNorth Miami, United StatesOkeechobee, United StatesChicago, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
71
Phase
PHASE2
Primary Completion Date
2022-06-17
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator
person